Huseyin Naci

Best Publications

• Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

  Courtney Davis;Huseyin Naci;Evrim Gurpinar;Elita Poplavska

  668
  Citations

• From "retailers" to health care providers: Transforming the role of community pharmacists in chronic disease management.

  Elias Mossialos;Emilie Courtin;Huseyin Naci;Shalom Benrimoj

  539
  Citations

• Distribution of road traffic deaths by road user group: a global comparison

  H. Naci;Dan Chisholm;Timothy D. Baker

  436
  Citations

• Economic burden of multiple sclerosis: a systematic review of the literature.

  Huseyin Naci;Rachael Fleurence;Julie Birt;Amy Duhig

  265
  Citations

• Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials

  Huseyin Naci;Jasper J Brugts;Rachael Fleurence;Bernice Tsoi

  261
  Citations

• Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.

  Huseyin Naci;Huseyin Naci;Courtney Davis;Jelena Savović;Jelena Savović;Julian P T Higgins;Julian P T Higgins;Julian P T Higgins

  253
  Citations

• Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.

  Huseyin Naci;Katelyn R. Smalley;Aaron S. Kesselheim

  191
  Citations

• Cost effectiveness of strategies to combat road traffic injuries in sub-Saharan Africa and South East Asia: mathematical modelling study

  Daniel Chisholm;Huseyin Naci;Adnan Ali Hyder;Nhan T. Tran

  106
  Citations

• How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?

  Huseyin Naci;John P.A. Ioannidis

  92
  Citations

• Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.

  Neville Jackson;Dan Atar;Maria Borentain;Guenter Breithardt

  91
  Citations

• Cost Implications of Using Different ECG Criteria for Screening Young Athletes in the United Kingdom.

  Harshil Dhutia;Aneil Malhotra;Vincent Gabus;Ahmed Merghani

  86
  Citations

• The Critical Role Of Observational Evidence In Comparative Effectiveness Research

  Rachael L. Fleurence;Huseyin Naci;Jeroen P. Jansen

  85
  Citations

• Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States

  Maximilian Salcher-Konrad;Huseyin Naci;Courtney Davis

  79
  Citations

• Generating comparative evidence on new drugs and devices after approval

  Andrea Cipriani;Andrea Cipriani;John P A Ioannidis;Peter M Rothwell;Paul Glasziou

  78
  Citations

• Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe.

  Rick A Vreman;Huseyin Naci;Huseyin Naci;Wim G Goettsch;Aukje K Mantel-Teeuwisse

  75
  Citations

• Applying Multiple Criteria Decision Analysis to Comparative Benefit-Risk Assessment: Choosing among Statins in Primary Prevention.

  Tommi Tervonen;Huseyin Naci;Gert van Valkenhoef;Anthony E. Ades

  67
  Citations

• The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature.

  Huseyin Naci;Rachael Fleurence;Julie Birt;Amy Duhig

  66
  Citations

• Evidence of comparative efficacy should have a formal role in European drug approvals

  Corinna Sorenson;Huseyin Naci;Jonathan Cylus;Elias Mossialos

  63
  Citations

• Generating comparative evidence on new drugs and devices before approval

  Huseyin Naci;Maximilian Salcher-Konrad;Aaron Kesselheim;Beate Wieseler

  58
  Citations

• Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.

  Huseyin Naci;Olivier J. Wouters;Radhika Gupta;John P.A. Ioannidis

  42
  Citations